1580 related articles for article (PubMed ID: 33877531)
1. Systematic review and meta-analysis efficacy and safety of immune checkpoint inhibitors in advanced melanoma patients with anti-PD-1 progression: a systematic review and meta-analysis.
Alrabadi NN; Abushukair HM; Ababneh OE; Syaj SS; Al-Horani SS; Qarqash AA; Darabseh OA; Al-Sous MM; Al-Aomar SR; Ahmed YB; Haddad R; Al Qarqaz FA
Clin Transl Oncol; 2021 Sep; 23(9):1885-1904. PubMed ID: 33877531
[TBL] [Abstract][Full Text] [Related]
2. Combination anti-PD1 and ipilimumab therapy in patients with advanced melanoma and pre-existing autoimmune disorders.
Brown LJ; Weppler A; Bhave P; Allayous C; Patrinely JR; Ott P; Sandhu S; Haydon A; Lebbe C; Johnson DB; Long GV; Menzies AA; Carlino MS
J Immunother Cancer; 2021 May; 9(5):. PubMed ID: 33963010
[TBL] [Abstract][Full Text] [Related]
3. Anti-PD-1 therapy in patients with advanced melanoma and preexisting autoimmune disorders or major toxicity with ipilimumab.
Menzies AM; Johnson DB; Ramanujam S; Atkinson VG; Wong ANM; Park JJ; McQuade JL; Shoushtari AN; Tsai KK; Eroglu Z; Klein O; Hassel JC; Sosman JA; Guminski A; Sullivan RJ; Ribas A; Carlino MS; Davies MA; Sandhu SK; Long GV
Ann Oncol; 2017 Feb; 28(2):368-376. PubMed ID: 27687304
[TBL] [Abstract][Full Text] [Related]
4. Ipilimumab and nivolumab/pembrolizumab in advanced hepatocellular carcinoma refractory to prior immune checkpoint inhibitors.
Wong JSL; Kwok GGW; Tang V; Li BCW; Leung R; Chiu J; Ma KW; She WH; Tsang J; Lo CM; Cheung TT; Yau T
J Immunother Cancer; 2021 Feb; 9(2):. PubMed ID: 33563773
[TBL] [Abstract][Full Text] [Related]
5. Association Between Sex and Immune Checkpoint Inhibitor Outcomes for Patients With Melanoma.
Jang SR; Nikita N; Banks J; Keith SW; Johnson JM; Wilson M; Lu-Yao G
JAMA Netw Open; 2021 Dec; 4(12):e2136823. PubMed ID: 34854905
[TBL] [Abstract][Full Text] [Related]
6. Immune Checkpoint Inhibitors and Immune-Related Adverse Events in Patients With Advanced Melanoma: A Systematic Review and Network Meta-analysis.
Chang CY; Park H; Malone DC; Wang CY; Wilson DL; Yeh YM; Van Boemmel-Wegmann S; Lo-Ciganic WH
JAMA Netw Open; 2020 Mar; 3(3):e201611. PubMed ID: 32211869
[TBL] [Abstract][Full Text] [Related]
7. Comparative safety of immune checkpoint inhibitors in cancer: systematic review and network meta-analysis.
Xu C; Chen YP; Du XJ; Liu JQ; Huang CL; Chen L; Zhou GQ; Li WF; Mao YP; Hsu C; Liu Q; Lin AH; Tang LL; Sun Y; Ma J
BMJ; 2018 Nov; 363():k4226. PubMed ID: 30409774
[TBL] [Abstract][Full Text] [Related]
8. Association of Anti-Programmed Cell Death 1 Antibody Treatment With Risk of Recurrence of Toxic Effects After Immune-Related Adverse Events of Ipilimumab in Patients With Metastatic Melanoma.
Brunot A; Grob JJ; Jeudy G; Grange F; Guillot B; Kramkimel N; Mortier L; Le Corre Y; Aubin FF; Mansard S; Lebbé C; Blom A; Montaudie H; Giacchero D; Prey S; Legoupil D; Guyot A; Amini-Adle M; Granel-Brocard F; Meyer N; Dinulescu M; Edeline J; Campillo-Gimenez B; Lesimple T
JAMA Dermatol; 2020 Sep; 156(9):982-986. PubMed ID: 32667663
[TBL] [Abstract][Full Text] [Related]
9. Efficacy of PD-1-based immunotherapy after radiologic progression on targeted therapy in stage IV melanoma.
Kreft S; Gesierich A; Eigentler T; Franklin C; Valpione S; Ugurel S; Utikal J; Haferkamp S; Blank C; Larkin J; Garbe C; Schadendorf D; Lorigan P; Schilling B
Eur J Cancer; 2019 Jul; 116():207-215. PubMed ID: 31212163
[TBL] [Abstract][Full Text] [Related]
10. Retrospective study of advanced melanoma patients treated with ipilimumab after nivolumab: Analysis of 60 Japanese patients.
Fujisawa Y; Yoshino K; Otsuka A; Funakoshi T; Uchi H; Fujimura T; Matsushita S; Hata H; Okuhira H; Tanaka R; Nagai K; Ishida Y; Nakamura Y; Furudate S; Yamamura K; Imafuku K; Yamamoto Y
J Dermatol Sci; 2018 Jan; 89(1):60-66. PubMed ID: 29079332
[TBL] [Abstract][Full Text] [Related]
11. Evaluating the efficacy and safety of nivolumab and ipilimumab combination therapy compared to nivolumab monotherapy in advanced cancers (excluding melanoma): a systemic review and meta-analysis.
Rangwala HS; Fatima H; Ali M; Sunder S; Devi S; Rangwala BS; Abbas SR
J Egypt Natl Canc Inst; 2024 May; 36(1):14. PubMed ID: 38705953
[TBL] [Abstract][Full Text] [Related]
12. Neurotoxicity from immune-checkpoint inhibition in the treatment of melanoma: a single centre experience and review of the literature.
Spain L; Walls G; Julve M; O'Meara K; Schmid T; Kalaitzaki E; Turajlic S; Gore M; Rees J; Larkin J
Ann Oncol; 2017 Feb; 28(2):377-385. PubMed ID: 28426103
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of anti-PD-1 and anti-PD-1 combined with anti-CTLA-4 immunotherapy to advanced melanoma: A systematic review and meta-analysis of randomized controlled trials.
Hao C; Tian J; Liu H; Li F; Niu H; Zhu B
Medicine (Baltimore); 2017 Jun; 96(26):e7325. PubMed ID: 28658143
[TBL] [Abstract][Full Text] [Related]
14. Investigation of clinical factors associated with longer overall survival in advanced melanoma patients treated with sequential ipilimumab.
Muto Y; Kitano S; Tsutsumida A; Namikawa K; Takahashi A; Nakamura Y; Yamanaka T; Yamamoto N; Yamazaki N
J Dermatol; 2019 Jun; 46(6):498-506. PubMed ID: 30945333
[TBL] [Abstract][Full Text] [Related]
15. Single or dual immune checkpoint inhibitor as adjuvant therapy in advanced melanoma.
Fukumoto T; Horita N
Eur J Cancer; 2021 Apr; 147():140-141. PubMed ID: 33662688
[No Abstract] [Full Text] [Related]
16. Effectiveness of Immune Checkpoint Inhibitor with Anti-PD-1 Monotherapy or in Combination with Ipilimumab in Younger versus Older Adults with Advanced Melanoma.
Woo TE; Stukalin I; Ding PQ; Goutam S; Sander M; Ewanchuk B; Cheung WY; Heng DYC; Cheng T
Curr Oncol; 2023 Sep; 30(10):8936-8947. PubMed ID: 37887546
[No Abstract] [Full Text] [Related]
17. Immunotherapy Outcomes in Advanced Melanoma in Relation to Age.
Joshi K; Atwal D; Ravilla R; Pandey Y; Yarlagadda N; Kakadia S; Makhoul I; Hutchins L; Mahmoud F
Perm J; 2020; 24():. PubMed ID: 32097116
[TBL] [Abstract][Full Text] [Related]
18. Health care utilization and steroid-refractory toxicities from immune checkpoint inhibitors.
Wang LX; Quach HT; Moodabigil NV; Davis EJ; Sosman JA; Dusetzina SB; Johnson DB
Cancer; 2020 Jan; 126(2):322-328. PubMed ID: 31580492
[TBL] [Abstract][Full Text] [Related]
19. Ipilimumab alone or ipilimumab plus anti-PD-1 therapy in patients with metastatic melanoma resistant to anti-PD-(L)1 monotherapy: a multicentre, retrospective, cohort study.
Pires da Silva I; Ahmed T; Reijers ILM; Weppler AM; Betof Warner A; Patrinely JR; Serra-Bellver P; Allayous C; Mangana J; Nguyen K; Zimmer L; Trojaniello C; Stout D; Lyle M; Klein O; Gerard CL; Michielin O; Haydon A; Ascierto PA; Carlino MS; Lebbe C; Lorigan P; Johnson DB; Sandhu S; Lo SN; Blank CU; Menzies AM; Long GV
Lancet Oncol; 2021 Jun; 22(6):836-847. PubMed ID: 33989557
[TBL] [Abstract][Full Text] [Related]
20. Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial.
Hodi FS; Chiarion-Sileni V; Gonzalez R; Grob JJ; Rutkowski P; Cowey CL; Lao CD; Schadendorf D; Wagstaff J; Dummer R; Ferrucci PF; Smylie M; Hill A; Hogg D; Marquez-Rodas I; Jiang J; Rizzo J; Larkin J; Wolchok JD
Lancet Oncol; 2018 Nov; 19(11):1480-1492. PubMed ID: 30361170
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
